Literature DB >> 24533716

Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.

Hark Kyun Kim1, Jeffrey E Green.   

Abstract

Gastric cancer is the second most common cause of cancer death worldwide. Recent development of targeted agents provides clinicians with additional systemic treatment options to conventional cytotoxic agents. Predictive markers are undoubtedly important for guiding the appropriate use of targeted and cytotoxic agents. Currently, however, HER2 is the only predictive biomarker validated for gastric cancer. In this review, candidate predictive markers for response to other targeted agents and cytotoxic chemotherapeutic agents are discussed.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24533716      PMCID： PMC7670597          DOI： 10.2217/pgs.13.250

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  68 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

Review 2.  Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays.

Authors:  K Malinowsky; C Wolff; B Ergin; D Berg; K F Becker
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Expression of epidermal growth factor receptor in human gastric and colonic carcinomas.

Authors:  W Yasui; H Sumiyoshi; J Hata; T Kameda; A Ochiai; H Ito; E Tahara
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

4.  Predictive biomarkers for bevacizumab: are we there yet?

Authors:  Dipen Maru; Alan P Venook; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2013-04-02       Impact factor: 12.531

5.  ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

Authors:  R Metzger; C G Leichman; K D Danenberg; P V Danenberg; H J Lenz; K Hayashi; S Groshen; D Salonga; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; B Konda; L Leichman
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

Authors:  J A Chan; L S Blaszkowsky; P C Enzinger; D P Ryan; T A Abrams; A X Zhu; J S Temel; D Schrag; P Bhargava; J A Meyerhardt; B M Wolpin; P Fidias; H Zheng; S Florio; E Regan; C S Fuchs
Journal:  Ann Oncol       Date:  2011-01-07       Impact factor: 32.976

7.  Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers.

Authors:  Il-Jin Kim; Jae-Hyun Park; Hio Chung Kang; Yong Shin; Hye-Won Park; Hye-Rin Park; Ja-Lok Ku; Seok-Byung Lim; Jae-Gahb Park
Journal:  Hum Genet       Date:  2003-09-25       Impact factor: 4.132

8.  Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Authors:  D W Miles; S L de Haas; L Y Dirix; G Romieu; A Chan; X Pivot; P Tomczak; L Provencher; J Cortés; P R Delmar; S J Scherer
Journal:  Br J Cancer       Date:  2013-02-19       Impact factor: 7.640

9.  ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.

Authors:  J Wei; Z Zou; X Qian; Y Ding; L Xie; J J Sanchez; Y Zhao; J Feng; Y Ling; Y Liu; L Yu; R Rosell; B Liu
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

10.  Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

Authors:  A F C Okines; D Gonzalez de Castro; D Cunningham; I Chau; R E Langley; L C Thompson; S P Stenning; C Saffery; Y Barbachano; F Coxon; G Middleton; D Ferry; T Crosby; S Madhusudan; J Wadsley; J Waters; M Hall; D Swinson; A Robinson; D Smith; J S Reis-Filho; T S Waddell; L Puckey; S Hulkki Wilson; Z Eltahir; M Band; A Wotherspoon
Journal:  Eur J Cancer       Date:  2013-03-05       Impact factor: 9.162
View more
  4 in total

1.  ADRM1 gene amplification is a candidate driver for metastatic gastric cancers.

Authors:  Seok Hoon Jang; Jun Won Park; Hyo Rim Kim; Je Kyung Seong; Hark Kyun Kim
Journal:  Clin Exp Metastasis       Date:  2014-06-27       Impact factor: 5.150

2.  EPMA position paper in cancer: current overview and future perspectives.

Authors:  Godfrey Grech; Xianquan Zhan; Byong Chul Yoo; Rostyslav Bubnov; Suzanne Hagan; Romano Danesi; Giorgio Vittadini; Dominic M Desiderio
Journal:  EPMA J       Date:  2015-04-15       Impact factor: 6.543

3.  Associations between serum CA724 and HER2 overexpression among stage II-III resectable gastric cancer patients: an observational study.

Authors:  Xin-Zu Chen; Wei-Han Zhang; Hai-Ning Chen; Jian-Ping Liu; Du He; Yang Liu; Kai Liu; Xiao-Long Chen; Xian-Ming Mo; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Oncotarget       Date:  2016-04-26

4.  An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.

Authors:  Xiangyu Li; Hao Cai; Weicheng Zheng; Mengsha Tong; Hongdong Li; Lu Ao; Jing Li; Guini Hong; Mengyao Li; Qingzhou Guan; Sheng Yang; Da Yang; Xu Lin; Zheng Guo
Journal:  Oncotarget       Date:  2016-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.